Abstract 2049
Background
Resistance to chemo-radiation therapy is a substantial obstacle compromising treatment of advanced cervical cancer. We investigated if proteomic panel associated with radioresistance can predict the survival in locally advanced cervical cancer.
Methods
One hundred and eighty-one frozen tissue samples were prospectively obtained from patients with locally advanced cervical cancer before chemoradiation. To develop survival prediction model, expression of 22 total and phosphorylated proteins was evaluated by well-based reverse phase protein arrays. and selected proteins were validated by western blotting analysis and immunohistochemistry. The performance of models was internally and externally validated.
Results
Unsupervised clustering stratified patients into three major groups with different overall survival (OS, p = 0.001) and progression-free survival (PFS, p = 0.003) based on detection of BCL2, HER2, CD133, CAIX and ERCC1. reverse-phase protein array results significantly correlated with western blotting results (R2=0.856). The C-index of model was higher than clinical model in the prediction of OS (C-index of 0.86, and 0.62, respectively), and also in the prediction of PFS (C-index of 0.82, and 0.64, respectively). The Kaplan-Meier survival curve shows the dose-dependent prognostic significance of the risk score for PFS and OS. The multivariable Cox proportional hazard model confirmed that the risk score was an independent predictor of PFS (HR, 1.6; 95% CI, 1.4–1.9; p < 0.001) and OS (HR, 2.1; 95% CI, 1.7–2.5; p < 0.001).
Conclusions
A proteomic panel of BCL2, HER2, CD133, CAIX and ERCC1 independently predicted survival in locally advanced cervical cancer patients. This prediction model can help identify chemoradiation responsive tumors, and improve clinical outcome prediction in cervical cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Chel Hun Choi.
Funding
Samsung Medical Center.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
4732 - Progesterone Receptor Isoform Ratio Dictates Antiprogestins/Progestins Effects on Metastatic Breast Cancer Models
Presenter: Maria Abascal
Session: Poster Display session 2
Resources:
Abstract
5737 - PAM50 and CGH-array genomic characterization of HER2-Equivocal Breast Cancers defined by the 2018 ASCO/CAP recommendations.
Presenter: Carine Ngo
Session: Poster Display session 2
Resources:
Abstract
1096 - OncotypeDX® predictive nomogram for recurrence score output: a machine learning system based on quantitative immunochemistry analysis - ADAPTED01
Presenter: Fabio Marazzi
Session: Poster Display session 2
Resources:
Abstract
5426 - Geriatric parameters predict both disease-related and patient-reported outcomes in older patients with breast cancer
Presenter: Willeke van der Plas-Krijgsman
Session: Poster Display session 2
Resources:
Abstract
5865 - Patients with a 21-gene assay in South East London differ from the TAILORx trial population
Presenter: Charalampos Gousis
Session: Poster Display session 2
Resources:
Abstract
1312 - Predictive tools in adjuvant breast cancer – what is the standard of evidence supporting their utility? A literature review examining validation of Adjuvant!, Cancermath and NHS Predict
Presenter: Alice Loft
Session: Poster Display session 2
Resources:
Abstract
2445 - Oncologic outcome of invasive lobular carcinoma: Is it different from that of invasive ductal carcinoma?
Presenter: Hee Jun Choi
Session: Poster Display session 2
Resources:
Abstract
2476 - Pathologic response and survival efficacy in patients with initial nodal involvement after neoadjuvant chemotherapy in early breast cancer
Presenter: SERAFIN MORALES Murillo
Session: Poster Display session 2
Resources:
Abstract
3761 - Chemotherapy-induced amenorrhea: prognostic impact on premenopausal Egyptian patients with breast cancer
Presenter: Khaled Abdel Karim
Session: Poster Display session 2
Resources:
Abstract
4687 - Predicting the presence of breast cancer using circulating small RNA in the serum
Presenter: Yumiko Koi
Session: Poster Display session 2
Resources:
Abstract